Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Total Long-Term Liabilities : ¥77.6 Mil (As of Mar. 2025)

View and export this data going back to 2011. Start your Free Trial

What is Staidson (Beijing) Biopharmaceuticals Co Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Staidson (Beijing) Biopharmaceuticals Co's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was ¥77.6 Mil.

Staidson (Beijing) Biopharmaceuticals Co Total Long-Term Liabilities Historical Data

The historical data trend for Staidson (Beijing) Biopharmaceuticals Co's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staidson (Beijing) Biopharmaceuticals Co Total Long-Term Liabilities Chart

Staidson (Beijing) Biopharmaceuticals Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Long-Term Liabilities

Get a 7-Day Free Trial

68.31

79.61

83.68

103.38

78.40

Staidson (Beijing) Biopharmaceuticals Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Long-Term Liabilities	Get a 7-Day Free Trial															85.48	73.59	78.74	78.40	77.60

Staidson (Beijing) Biopharmaceuticals Co Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Staidson (Beijing) Biopharmaceuticals Co Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Staidson (Beijing) Biopharmaceuticals Co's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Staidson (Beijing) Biopharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Staidson (Beijing) Biopharmaceuticals Co Ltd (SZSE:300204) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rongjing Dong Street, No 5 Beijing Economic and Technological Development Zone, Beijing, CHN, 100176

Website

http://www.staidson.com

Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.

Executives

Zhang Hong Shan	Supervisors
Zheng Hong	Supervisors
Cheng Jiang Hong	Executives
Feng Yu Jing	Executives
Ma Li Na	Secretary, Director
Zhou Zhi Wen	Director
Wang Huan	Securities Affairs Representative
Zhang Rong Qin	Executives
Xu Jiang Ping	Executives
Cao Hai Yan	Supervisors
Sun Yan Fang	Executives
Jiang Li Xin	Director
Gu Jian Ping	Director
Xu Xiang Qing	Supervisors
Gu Zhen Qi	Director

Staidson (Beijing) Biopharmaceuticals Co Headlines

No Headlines